Bli medlem
Bli medlem

Du är här

2016-03-04

LivaNova, PLC Announces Appointment of Vice President Investor Relations and Corporate Communications

LivaNova PLC
Press release

LivaNova, PLC Announces Appointment of Vice President Investor Relations and
Corporate Communications

LONDON, 2016-03-03 15:00 CET (GLOBE NEWSWIRE) --
LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN), a global medical technology company and
a leader in the treatment of cardiovascular diseases, today announced that it
has appointed Karen M. King as Vice President, Investor Relations and Corporate
Communications.

Ms. King brings more than 25 years of experience in a broad array of industries
to her role at LivaNova. For the last seven years, she was Corporate Vice
President, Investor Relations at Hospira, a leading provider of injectable
drugs and infusion technologies, and a global leader in biosimilars. At
Hospira, Ms. King was responsible for developing and executing strategies to
build relationships with investment analysts and shareholders as well as to
align Hospira’s market capitalization with the intrinsic value of the company.

Previously, Ms. King served as the Vice President of Investor Relations of
Career Education Corporation, one of the largest global providers of private,
for-profit postsecondary education. Prior to Career Education Corporation, Ms.
King worked in various investor relations and financial analyst roles.

“Karen brings a wide variety of experience to LivaNova, including the
development of comprehensive and global strategic investor relations programs,”
commented Vivid Sehgal, LivaNova’s Chief Financial Officer. “We are delighted
to welcome Karen as a key member of our senior management team.”

Ms. King earned her bachelor’s degree in business from Indiana University in
the United States.

About LivaNova

LivaNova PLC, headquartered in London, UK, is a global medical technology
company formed by the merger of Sorin S.p.A, a leader in the treatment of
cardiovascular diseases, and Cyberonics Inc., a medical device company with
core expertise in neuromodulation. LivaNova transforms medical innovation into
meaningful solutions for the benefit of patients, healthcare professionals, and
healthcare systems. The company employs approximately 4,500 employees
worldwide. With a presence in more than 100 countries, LivaNova operates as
three business units: Cardiac Rhythm Management, Cardiac Surgery, and
Neuromodulation, with operating headquarters in Clamart (France), Mirandola
(Italy) and Houston (U.S.A.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s
Financial Conduct Authority and traded on London Stock Exchange (LSE) under the
ticker symbol “LIVN”.

Safe harbor statement

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements can be
identified by the use of forward-looking terminology, including "may,"
"believe," "will," "expect," "anticipate," "estimate," "plan," "intend,"
"forecast," or other similar words. Statements contained in this press release
are based on information presently available to LivaNova and assumptions that
the parties believe to be reasonable. LivaNova is not assuming any duty to
update this information if those facts change or if the assumptions are no
longer believed to be reasonable. Investors are cautioned that all such
statements involve risks and uncertainties, including without limitation,
statements concerning developing novel opportunities in heart failure, sleep
apnea and percutaneous mitral valve, creating new innovative solutions that
benefit patients, healthcare professionals, and healthcare systems, and
building significant shareholder value. Important factors that may cause
actual results to differ include, but are not limited to: risks that the new
businesses will not be integrated successfully or that the combined companies
will not realize estimated cost savings, value of certain tax assets, synergies
and growth, or that such benefits may take longer to realize than expected; the
inability of LivaNova to meet expectations regarding the timing, completion and
accounting and tax treatments; risks relating to unanticipated costs of
integration, including operating costs, customer loss or business disruption
being greater than expected; reductions in customer spending, a slowdown in
customer payments and changes in customer demand for products and services;
unanticipated changes relating to competitive factors in the industries in
which the company operates; the ability to hire and retain key personnel; the
ability to attract new customers and retain existing customers in the manner
anticipated; reliance on and integration of information technology systems;
changes in legislation or governmental regulations affecting the company;
international, national or local economic, social or political conditions that
could adversely affect the company or its customers; conditions in the credit
markets; risks to the industries in which LivaNova operates that are described
in the "Risk Factors" section of the Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and other documents filed from time to time with the SEC
by Cyberonics, Inc. and LivaNova and the analogous section in annual reports
and other documents filed from time to time by Sorin S.p.A. with the Italian
financial market regulator (CONSOB); risks associated with assumptions made in
connection with critical accounting estimates and legal proceedings; LivaNova’s
international operations, which are subject to the risks of currency
fluctuations and foreign exchange controls; and the potential of international
unrest, economic downturn or effects of currencies, tax assessments, tax
adjustments, anticipated tax rates, raw material costs or availability, benefit
or retirement plan costs, or other regulatory compliance costs. The foregoing
list of factors is not exhaustive. You should carefully consider the foregoing
factors and the other risks and uncertainties that affect the parties'
businesses, including those described in Cyberonics' Annual Report on Form
10-K, as amended from time to time, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other documents filed from time to time with the SEC by
Cyberonics and LivaNova and those described in Sorin's annual reports,
registration documents and other documents filed from time to time with CONSOB
by Sorin. LivaNova does not give any assurance (1) that LivaNova will achieve
its expectations, or (2) concerning any result or the timing thereof, in each
case, with respect to any regulatory action, administrative proceedings,
government investigations, litigation, warning letters, consent decree, cost
reductions, business strategies, earnings or revenue trends or future financial
results.

For more information, please visit www.livanova.com, or contact:

Investor Relations:
Vivid Sehgal
Chief Financial Officer
e-mail: investor.relations@livanova.com

Investor Relations and Media:
Greg Browne
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.